Figure 1. Results from two new trials and two new meta-analyses conclusively demonstrate the cardio-protective and kidney-protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors across the breadth of heart failure and chronic kidney disease populations studied, with absolute benefits convincingly outweighing the potential harms.
Key: CV = cardiovascular; eGFR = estimated glomerular filtration rate; SE = standard error; SGLT2i = sodium-glucose co-transporter 2 inhibitor
Full details of methodology are available from reference 4.